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with salary, stock options, and shares in the same.A highly condensed history of molecular biology could be
said to have begun with the foundational work that led to
Watson’s and Crick’s seminal discovery of the double he-
lical nature of DNA. A golden age of molecular biology
followed during which time tools were developed that
became integral to the laboratory medicine discipline that
has come to be known, more or less synonymously, as
molecular diagnostics, molecular genetics, and molecular
pathology. (In a nod toward this taxonomic elasticity, the
American Board of Pathology and the American Board of
Medical Genetics recognized, in 2001, subspecialty cre-
dentialing using the cumbersome but ecumenical term
molecular genetic pathology.) Restriction endonuclease
digestion, nucleic acid hybridization, Southern and Northern
blotting, positional cloning, PCR and other in vitro nucleic
acid ampliﬁcation technologies, DNA sequencing, and other
tools were seized upon by laboratorians to ignite this rev-
olutionary ﬁeld. The innovative approaches these molecular
tools enabled have been applied, to lesser or greater degrees,
in nearly all branches of medicine, serving as but a prelude
to the inevitability of genomic applications even more
broadly in the future. Has molecular diagnostics been
transformative? The answer is arguable, but the path toward
a positive answer seems clear. Does a quick Star Trekelike
medical tricorder scan of the patient in the emergency
department to learn his or her pharmacogenomic proﬁle
before drugs are administered sound as crazy in 2014 as it
did in 1994? Think about what the answer to that question
might be in 2034.
In keeping with the great tradition of science that all
discoveries rest on the shoulders of giants, Y.W. Kan andCopyright ª 2014 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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http://dx.doi.org/10.1016/j.jmoldx.2014.06.010his team, in the late 1970s, applied some of these technol-
ogies in the diagnosis of thalassemias1 and hemoglobinop-
athies2 or, put another way, molecular diagnostics was born.
Soon thereafter, Southern blotting became an important
adjunctive diagnostic tool for genotyping leukemias and
lymphomas. The assessment of HER-2/neu gene ampliﬁ-
cation in node-positive breast cancer, as described by Sla-
mon et al3 using Southern blots in 1989, not only paved the
way for breast cancer prognostication but also planted the
seeds for precision medicine and other terms that became
commonplace 20 years later (ie, companion diagnostics and
targeted therapy). During this same two-decade period, the
application of PCR to the detection of infectious agents
transformed the test menus of all microbiology and virology
laboratories and created some of the most high-volume,
high-impact molecular pathology tests (eg, quantitative
HIV and hepatitis C virus monitoring and detection of
Chlamydia trachomatis, Neisseria gonorrhoeae, and human
papillomavirus).
It was apparent in the late 1980s to several visionaries in
academic pathology that the tools of molecular biology
would notably change the practice of laboratory medicine.
Their efforts at organizing the community through various
molecular diagnostics and molecular pathology meetings of
practitioners are well documented by the ﬁrst executive
Farkasofﬁcer of the Association for Molecular Pathology (AMP),
Dr. Frances Pitlick, in the October 2004 issue of the AMP
Newsletter (http://www.amp.org/about/newsletters/archive/
10thann-04.pdf, last accessed June 23, 2014). The birth of
AMP in 1995 gave a societal home to the professionals prac-
ticing the tools of genomics, even beforewe knew to call it that.
Prospectively, 20 years is a long time. Retrospectively, it
is the blink of an eye. Sixty years ago, the discovery of the
double helical nature of DNA had only been in the scientiﬁc
literature for a year. Forty years ago, although we knew how
to purify DNA, the ﬁrst tools of molecular biology (eg,
restriction endonucleases) were being used, but the main-
stays of molecular pathology investigation (eg, Southern
blotting, nucleic acid ampliﬁcation, and sequencing) had not
yet been developed. Twenty years ago, the evolution from
conventional to real-time PCR was in its infancy,4 and the
herculean effort of sequencing the human genome was less
than half done.
Today, molecular pathologists are once again at the fore-
front of the evolution of laboratory medicine investigation as
we move from ampliﬁcation-based assays for detection of
single analytes and static arrayebased assays for low-, me-
dium-, and high-density panels to the ultimate laboratory test:
the newest iteration of DNA sequencing. Alternatively called
next-generation sequencing and massively parallel shotgun
sequencing, it seems clear that the adjective next generation
will have to change. Sequencing today is the harbinger of the
ultimate laboratory test. Many or most, perhaps even all,
molecular pathology questions, whether diagnostic, prog-
nostic, therapeutic, or for monitoring, have their answers
locked in the genome or exome, and next-generation DNA
sequencing is the key to those answers. The technology is
already being applied clinically hundreds of thousands of600times annually for noninvasive detection in pregnant women
of fetal aneuploidy or euploidy and, at lesser frequency, in
oncology and cardiology workups. DNA sequencing, the
ultimate genomic laboratory tool, will be as ubiquitous in 20
years as the microscope has been for anatomical pathology,
hematology-oncology, and microbiology; indeed, DNA
sequencing is the genomic equivalent of the microscope.
That molecular pathologists are the stewards of this new
technology augurs well for the AMP, its members, and the
physicians and patients we serve. We, as members and
readers of The Journal of Molecular Diagnostics, look for-
ward to reading the 2034 version of this article celebrating
AMP’s 40th anniversary to learn if our predictions rang true.Acknowledgments
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